Treatment of men with rising prostate-specific antigen levels following radical prostatectomy

Katherine Tzou, Winston W. Tan, Steven Buskirk

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Approximately one-third of patients who undergo radical prostatectomy for prostate cancer will develop a detectable prostate-specific antigen (PSA) level within 10 years. Biochemical recurrence of disease is defined as a rising PSA level in the absence of clinical or radiographic evidence of disease. Management of PSA recurrence is controversial, as prostate cancer may take an indolent course, or it may aggressively develop into metastatic disease. The only potentially curative treatment for biochemical failure after prostatectomy is salvage radiotherapy. Noncurative treatment options include hormone therapy or clinical trials of a novel systemic agent. This article will address management options for a rising PSA level after prostatectomy, as well as ongoing studies exploring molecular biomarkers as prognostic tumor markers and potential targets for prostate cancer therapy.

Original languageEnglish (US)
Pages (from-to)125-136
Number of pages12
JournalExpert review of anticancer therapy
Issue number1
StatePublished - Jan 1 2011


  • androgen-deprivation therapy
  • biochemical recurrence
  • prostate cancer
  • salvage radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Treatment of men with rising prostate-specific antigen levels following radical prostatectomy'. Together they form a unique fingerprint.

Cite this